Folia Biologica
Journal of Cellular and Molecular Biology, Charles University 

Jan Bubeník

• Interleukin 12 in Cancer Treatment

  Jan Bubeník

  2011, Vol. 57, Issue 1, pp. 1-2
• Gene Therapy of Cancer by Vaccines Carrying Inserted Immunostimulatory Genes

  Jan Bubeník

  2007, Vol. 53, Issue 3, pp. 71-73
• Depletion of T_reg Cells Augments the Therapeutic Effect of Cancer Vaccines

  Jan Bubeník

  2006, Vol. 52, Issue 6, pp. 202-204
• Human Papillomavirus (HPV) and HPV-Associated Tumour Vaccines

  Jan Bubeník

  2006, Vol. 52, Issue 1-2, pp. 45-46
• MHC Class I Downregulation, Tumour Escape from Immune Surveillance and Design of Therapeutic Strategies

  Jan Bubeník

  2005, Vol. 51, Issue 1, pp. 1-2
• Interleukin-2 Therapy of Cancer

  Jan Bubeník

  2004, Vol. 50, Issue 3-4, pp. 120-130
• Dedication to Professor Jan Svoboda, Ph.D., D.Sc.

  Jan Bubeník

  2004, Vol. 50, Issue 3-4, pp. 77-77
• Prospects for Immunotherapy of MHC Class I-Deficient Tumours

  Jan Bubeník

  2003, Vol. 49, Issue 3, pp. 95-99

The following name might also represent this author:

J. Bubeník

• Genetically Modified Vaccines Augment the Efficacy of Cancer Surgery and Chemotherapy

  J. Bubeník

  2009, Vol. 55, Issue 6, pp. 199-200
• Immunotherapeutic Efficacy of Vaccines Generated by Fusion of Dendritic Cells and HPV16-Associated Tumour Cells

  Jana Šímová, J. Bubeník, J. Bieblová, M. Indrová, T. Jandlová

  2005, Vol. 51, Issue 1, pp. 19-24
• The Role of NK1.1⁺ Cells in the Protection against MHC Class I⁺ HPV16-Associated Tumours

  Jana Šímová, J. Bubeník, J. Bieblová, T. Jandlová

  2004, Vol. 50, Issue 6, pp. 200-202
• Immunogenicity of Dendritic Cell-Based HPV16 E6/E7 Peptide Vaccines: CTL Activation and Protective Effects

  Marie Indrová, M. Reiniš, J. Bubeník, T. Jandlová, J. Bieblová, V. Vonka, J. Velek

  2004, Vol. 50, Issue 6, pp. 184-193
• MHC Class I⁺ and Class I^- HPV16-Associated Tumours Expressing the E7 Oncoprotein Do Not Cross-react in Immunization/Challenge Experiments

  Jana Šímová, R. Mikyšková, V. Vonka, J. Bieblová, J. Bubeník, T. Jandlová

  2003, Vol. 49, Issue 6, pp. 230-234
• Adjuvant Cytokine Treatment of Minimal Residual Disease after Surgical Therapy in Mice Carrying HPV16-Associated Tumours: Cytolytic Activity of Spleen Cells from Tumour Regressors

  Marie Indrová, R. Mikyšková, T. Jandlová, V. Vonka, J. Bubeník, J. Bieblová

  2003, Vol. 49, Issue 6, pp. 217-222
• Immunotherapy of HPV 16-Associated Tumours with Tumour Cell Line/Dendritic Cell Line (TC-1/DC2.4) Hybrid Vaccines

  Jana Šímová, J. Bieblová, T. Jandlová, J. Bubeník

  2003, Vol. 49, Issue 5, pp. 203-206
• Local IFN-γ Therapy of HPV16-Associated Tumours

  Romana Mikyšková, J. Bieblová, J. Šímová, M. Indrová, T. Jandlová, V. Vonka, M. Šmahel, J. Bubeník, L. Mendoza

  2003, Vol. 49, Issue 1, pp. 26-32
• Freezing and Thawing of Murine Bone Marrow-Derived Dendritic Cells Does Not Alter Their Immunophenotype and Antigen Presentation Characteristics

  Luis Mendoza, J. Bubeník, M. Indrová, J. Bieblová, V. Vonka, J. Šímová

  2002, Vol. 48, Issue 6, pp. 242-245